Results 41 to 50 of about 22,314 (175)

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Real‐world study of the use of azacitidine in myelodysplasia in Australia

eJHaem
Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation.
Anoop Enjeti, Asma Ashraf, Vincent Caillet, Arif Alam, Jonathan Silar, Harold Keer, Francesco Castaldi, Taleisha Paine   +7 more
doaj   +1 more source

Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management

Frontiers in Oncology
Azacitidine, a hypomethylating agent, has caused a paradigm shift in the outcomes of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not eligible for stem cell transplantation, particularly in combination with BCL2 ...
Ruah Alyamany, Ahmed Alnughmush, Malak Almutlaq, Mohammed Alyamany, Mansour Alfayez   +4 more
doaj   +1 more source

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells [PDF]

, 2015
Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/ITD) are lacking and represent a significant unmet need. Recent data on the
Chang, Emily, Ganguly, Sudipto, Gocke, Christopher D., Konig, Heiko, Levis, Mark, Rajkhowa, Trivikram   +5 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

The blind men and the AML elephant:can we feel the progress? [PDF]

, 2016
The pharmacological therapy of non-promyelocytic acute myeloid leukemia (AML) has remained unchanged for over 40 years with an anthracycline–cytarabine combination forming the backbone of induction treatments.
A Wanquet, AK Burnett, AK Burnett, AK Burnett, AK Burnett, AK Burnett, AK Burnett, AM Perry, D Garfield, DW Milligan, EL Korn, Experts in Chronic Myeloid Leukemia, F Ravandi, F Ravandi, F Turturro, H Dombret, HF Fernandez, I Gojo, J Loke, K Wheatley, K Wheatley, LR Silverman, M Lübbert, M Weil, MR Luskin, MW Drummond, NI Cherny, P Fenaux, P Greenberg, P Paschka, PB Bach, PF Bross, RC Young, RK Hills, S Amadori, S Castaigne, SH Petersdorf, SY Zafar, ZY Wang   +38 more
core   +3 more sources

An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia [PDF]

, 2020
Recent advances in non-intensive therapy (non-IC) have demonstrated the potential for improved outcomes in patients with non-promyelocytic acute myeloid leukaemia (AML) unsuitable for intensive chemotherapy [1].
Bedair, Khaled, Ip, Keith, Tauro, Sudhir
core   +2 more sources

Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha, Bishwas Mandal, Vishal Mandal, Asis Shrestha, Amir Babu Shrestha   +4 more
wiley   +1 more source

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.

PLoS ONE, 2020
Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten ...
Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher, Eric Delabesse   +15 more
doaj   +2 more sources

Effects of Cyclosporine and Azacitidine on Some Hematologic and ‎Biochemical Parameters of Benzene-Induced Aplastic Anemia in Rats

The Iraqi Journal of Veterinary Medicine, 2023
Aplastic anemia, marked by deficiencies in hematopoietic stem cells, leads to peripheral blood pancytopenia and hypocellular bone ‎marrow. This study aimed to evaluate the therapeutic efficacy of cyclosporine and azacitidine, administered either ...
ghanem taher, Huda F Hasn
doaj   +1 more source